, 21(3), 181–200. https://www.nature.com/articles/s41573-021-00371-6

Ottis, P., et al. (2017). PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery. BioEssays, 39(12), 1700247. https://onlinelibrary.wiley.com/doi/full/10.1002%2Fbies.201700247

CAS. (n.d.). PROTACs revolutionize small molecule drugs. CAS Insights. https://www.cas.org/resources/cas-insights/protac-drug-development

Scott, D. C., et al. (2017). Crystal Structure of the Cul2-Rbx1-EloBC-VHL Ubiquitin Ligase Complex. Structure, 25(7), 1152-1160.e3. https://www.cell.com/structure/fulltext/S0969-2126(17)30127-2

Eichner, R., et al. (2023). Targeting E3 ubiquitin ligases and their adaptors as a therapeutic strategy. Experimental & Molecular Medicine, 55, 2333–2344. https://www.nature.com/articles/s12276-023-01087-w

Chen, Y., et al. (2022). An integrative pan-cancer analysis revealing the difference of RBX1 between tumor and normal tissues. Frontiers in Immunology, 13, 968777. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.968777/full